

**GUJARAT TECHNOLOGICAL UNIVERSITY****M. Pharm - SEMESTER-III • EXAMINATION – SUMMER-2016****Subject Code: 1931501****Date: 27/05/2016****Subject Name: Drug regulation and Regulatory Authority****Time: 2:30 PM to 5:30 PM****Total Marks: 80****Instructions:**

- 1. Attempt any five questions.**
- 2. Make suitable assumptions wherever necessary.**
- 3. Figures to the right indicate full marks.**

|             |            |                                                                                 |           |
|-------------|------------|---------------------------------------------------------------------------------|-----------|
| <b>Q.1</b>  | <b>(a)</b> | Explain in detail Drug Master File.                                             | <b>06</b> |
|             | <b>(b)</b> | Write a note on medical device registration as per 510k .                       | <b>05</b> |
|             | <b>(c)</b> | Explain the format and contents of NDA.                                         | <b>05</b> |
| <b>Q.2</b>  | <b>(a)</b> | Write a note on WHO certification scheme on Quality of Pharmaceutical products. | <b>06</b> |
|             | <b>(b)</b> | Explain the Procedure for price fixing of Drug substance and Drug Product.      | <b>05</b> |
|             | <b>(c)</b> | Write a note on National Formulary of India.                                    | <b>05</b> |
| <b>Q.3</b>  | <b>(a)</b> | Explain the Standard format of Monograph as per IP.                             | <b>06</b> |
|             | <b>(b)</b> | Give Emphasis on IP Review Process.                                             | <b>05</b> |
|             | <b>(c)</b> | Write a note on Site Master File.                                               | <b>05</b> |
| <b>Q.4</b>  | <b>(a)</b> | Write a note on GCP as per US.                                                  | <b>06</b> |
|             | <b>(b)</b> | Define Pharmacovigilance. Explain ADR reporting system in India and US.         | <b>05</b> |
|             | <b>(c)</b> | Write a note on Toxicological studies as per ICH guidelines.                    | <b>05</b> |
| <b>Q.5</b>  | <b>(a)</b> | Classify medical device. Explain in detail PMA process in detail.               | <b>06</b> |
|             | <b>(b)</b> | Define Haemovigilance. Explain Adverse event reporting system as per India.     | <b>05</b> |
|             | <b>(c)</b> | Explain labeling requirements for drugs as per D &C act.                        | <b>05</b> |
| <b>Q. 6</b> | <b>(a)</b> | Explain Objectives and functions of CDL and DTAB.                               | <b>06</b> |
|             | <b>(b)</b> | Write a note on NDA as per EUDRA guidelines.                                    | <b>05</b> |
|             | <b>(c)</b> | Explain the process involved in Harmonization of Pharmacopieal standards.       | <b>05</b> |
| <b>Q.7</b>  | <b>(a)</b> | Explain the clinical evaluation process as per US and Europe.                   | <b>06</b> |
|             | <b>(b)</b> | Explain WHO guidelines with emphasis on International registration.             | <b>05</b> |
|             | <b>(c)</b> | Write a note on electronic CTD.                                                 | <b>05</b> |

\*\*\*\*\*